Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide and dexamethasone after radiotherapy for high-risk solitary bone plasmacytoma
2015-001355-76Phase 3Unknown
- Sponsor
- University College London
- Start
- Mar 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lenalidomide and dexamethasone in solitary bone plasmacytoma (SBP) (2 arms), sponsored by University College London. Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
lenalidomidedexamethasone
03
Conditions
solitary bone plasmacytoma (SBP)
Beyond the preview
Go deeper on 2015-001355-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001355-76.